At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Study to Test Radium-223 with Docetaxel in Patients with Prostate Cancer
This is an open-labeled, randomized, phase III study of docetaxel versus docetaxel in combination with radium-223 in subjects with mCRPC.
In order to participate you must have:
- Have histological or cytological proof of prostate cancer.
- Have received external beam radiotherapy within the 4 weeks prior to randomization.
- Have received four or more systemic anticancer regimens for mCRPC.
This is a partial list of inclusion and exclusion criteria.